Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Gastric Bypass | 11 | 2022 | 824 | 3.320 |
Why?
|
Bone Density | 36 | 2024 | 3573 | 3.030 |
Why?
|
Osteoporosis | 14 | 2023 | 1606 | 2.520 |
Why?
|
Obesity, Morbid | 7 | 2020 | 1300 | 1.670 |
Why?
|
Bone Diseases, Metabolic | 5 | 2022 | 411 | 1.470 |
Why?
|
Absorptiometry, Photon | 18 | 2023 | 1757 | 1.470 |
Why?
|
Bariatric Surgery | 6 | 2020 | 1001 | 1.430 |
Why?
|
Gastroplasty | 3 | 2020 | 159 | 1.240 |
Why?
|
Fractures, Bone | 8 | 2024 | 2063 | 1.200 |
Why?
|
Bone Remodeling | 6 | 2018 | 583 | 1.100 |
Why?
|
Osteoporosis, Postmenopausal | 4 | 2021 | 399 | 1.030 |
Why?
|
Radius | 9 | 2023 | 443 | 0.990 |
Why?
|
Postmenopause | 9 | 2021 | 2519 | 0.950 |
Why?
|
Gastrectomy | 3 | 2021 | 693 | 0.910 |
Why?
|
Libido | 3 | 2020 | 124 | 0.890 |
Why?
|
Bone and Bones | 11 | 2023 | 2589 | 0.880 |
Why?
|
Osteonecrosis | 2 | 2022 | 230 | 0.790 |
Why?
|
Bone Density Conservation Agents | 6 | 2022 | 797 | 0.770 |
Why?
|
Goserelin | 3 | 2020 | 126 | 0.740 |
Why?
|
Teriparatide | 2 | 2014 | 226 | 0.700 |
Why?
|
Testosterone | 5 | 2020 | 2494 | 0.690 |
Why?
|
Adipose Tissue | 5 | 2021 | 3335 | 0.670 |
Why?
|
Histamine H2 Antagonists | 2 | 2011 | 169 | 0.620 |
Why?
|
Magnetite Nanoparticles | 4 | 2024 | 313 | 0.570 |
Why?
|
Osteoporotic Fractures | 4 | 2024 | 417 | 0.570 |
Why?
|
Bone Resorption | 3 | 2018 | 728 | 0.560 |
Why?
|
Tibia | 8 | 2023 | 1076 | 0.560 |
Why?
|
Bone Marrow | 2 | 2016 | 2935 | 0.530 |
Why?
|
Eunuchism | 1 | 2016 | 19 | 0.520 |
Why?
|
Body Composition | 9 | 2019 | 2461 | 0.520 |
Why?
|
Bone Diseases | 1 | 2019 | 416 | 0.510 |
Why?
|
Insulin Resistance | 3 | 2020 | 3982 | 0.500 |
Why?
|
Subcutaneous Fat | 2 | 2017 | 403 | 0.490 |
Why?
|
Proton Pump Inhibitors | 2 | 2011 | 553 | 0.470 |
Why?
|
Intra-Abdominal Fat | 2 | 2017 | 624 | 0.430 |
Why?
|
Ferric Compounds | 4 | 2020 | 377 | 0.420 |
Why?
|
Adiposity | 2 | 2020 | 1895 | 0.420 |
Why?
|
Parathyroid Hormone | 4 | 2016 | 1803 | 0.410 |
Why?
|
Pelvic Bones | 3 | 2020 | 274 | 0.410 |
Why?
|
Magnetics | 4 | 2021 | 599 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 10 | 2024 | 20776 | 0.400 |
Why?
|
Femur Neck | 3 | 2024 | 318 | 0.390 |
Why?
|
Obesity | 8 | 2023 | 13087 | 0.370 |
Why?
|
Intestines | 1 | 2020 | 1911 | 0.360 |
Why?
|
Bone Morphogenetic Proteins | 2 | 2012 | 847 | 0.330 |
Why?
|
Energy Metabolism | 1 | 2020 | 2905 | 0.310 |
Why?
|
Middle Aged | 41 | 2024 | 223740 | 0.280 |
Why?
|
Pandemics | 4 | 2022 | 8745 | 0.270 |
Why?
|
Humans | 75 | 2024 | 768887 | 0.260 |
Why?
|
Diagnostic Imaging | 5 | 2020 | 3538 | 0.250 |
Why?
|
Body Mass Index | 4 | 2019 | 13054 | 0.250 |
Why?
|
Spine | 3 | 2018 | 1141 | 0.240 |
Why?
|
Delivery of Health Care | 3 | 2023 | 5375 | 0.240 |
Why?
|
Hip | 2 | 2017 | 255 | 0.240 |
Why?
|
Oxytocin | 2 | 2020 | 403 | 0.230 |
Why?
|
Male | 40 | 2024 | 365249 | 0.230 |
Why?
|
Estradiol | 4 | 2017 | 1952 | 0.230 |
Why?
|
Female | 46 | 2024 | 397464 | 0.220 |
Why?
|
Hip Fractures | 3 | 2018 | 996 | 0.220 |
Why?
|
Lumbar Vertebrae | 4 | 2022 | 1889 | 0.220 |
Why?
|
Femur | 2 | 2024 | 1320 | 0.210 |
Why?
|
Medicare | 2 | 2019 | 6888 | 0.210 |
Why?
|
Cell Tracking | 2 | 2021 | 140 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3116 | 0.200 |
Why?
|
Propensity Score | 3 | 2020 | 1968 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3239 | 0.200 |
Why?
|
Peptide YY | 1 | 2022 | 135 | 0.200 |
Why?
|
Fanconi Syndrome | 1 | 2022 | 35 | 0.200 |
Why?
|
Nanomedicine | 1 | 2024 | 292 | 0.190 |
Why?
|
Hematopoietic Stem Cells | 1 | 2014 | 3408 | 0.190 |
Why?
|
Aging | 1 | 2020 | 8765 | 0.190 |
Why?
|
Practice Guidelines as Topic | 3 | 2013 | 7460 | 0.180 |
Why?
|
Diabetes Mellitus, Type 2 | 2 | 2015 | 12252 | 0.180 |
Why?
|
Risk Assessment | 4 | 2024 | 24330 | 0.180 |
Why?
|
Weight Loss | 3 | 2019 | 2720 | 0.180 |
Why?
|
Adult | 29 | 2021 | 223818 | 0.180 |
Why?
|
Hypopituitarism | 2 | 2020 | 252 | 0.180 |
Why?
|
Penile Erection | 1 | 2020 | 101 | 0.170 |
Why?
|
Postoperative Complications | 2 | 2020 | 15889 | 0.170 |
Why?
|
Diabetes Insipidus, Neurogenic | 1 | 2020 | 20 | 0.170 |
Why?
|
X-Ray Microtomography | 1 | 2022 | 457 | 0.170 |
Why?
|
Diabetes Mellitus, Type 1 | 2 | 2024 | 3447 | 0.170 |
Why?
|
Anti-Mullerian Hormone | 1 | 2022 | 420 | 0.160 |
Why?
|
Gels | 1 | 2020 | 422 | 0.160 |
Why?
|
Aged | 21 | 2024 | 171790 | 0.160 |
Why?
|
Muscle Strength | 2 | 2013 | 641 | 0.160 |
Why?
|
Anorexia Nervosa | 2 | 2019 | 1364 | 0.160 |
Why?
|
Body Fat Distribution | 1 | 2020 | 246 | 0.160 |
Why?
|
Injections, Subcutaneous | 1 | 2020 | 687 | 0.160 |
Why?
|
Risk Factors | 12 | 2024 | 74971 | 0.150 |
Why?
|
Models, Animal | 2 | 2016 | 2123 | 0.150 |
Why?
|
Congresses as Topic | 2 | 2013 | 811 | 0.150 |
Why?
|
Fractures, Spontaneous | 1 | 2020 | 232 | 0.150 |
Why?
|
Vasopressins | 1 | 2020 | 358 | 0.150 |
Why?
|
Administration, Cutaneous | 1 | 2020 | 716 | 0.150 |
Why?
|
Computer Simulation | 1 | 2012 | 6289 | 0.150 |
Why?
|
Diphosphonates | 2 | 2022 | 634 | 0.150 |
Why?
|
Thrombophilia | 1 | 2020 | 308 | 0.140 |
Why?
|
Central Cord Syndrome | 1 | 2016 | 5 | 0.140 |
Why?
|
Unnecessary Procedures | 1 | 2020 | 419 | 0.140 |
Why?
|
Mass Screening | 1 | 2012 | 5455 | 0.130 |
Why?
|
Hyperthermia, Induced | 1 | 2020 | 416 | 0.130 |
Why?
|
Hydroxycholecalciferols | 1 | 2015 | 44 | 0.130 |
Why?
|
United States | 14 | 2024 | 73180 | 0.130 |
Why?
|
Galactose | 1 | 2017 | 300 | 0.130 |
Why?
|
Aerosols | 1 | 2018 | 636 | 0.120 |
Why?
|
Dextrans | 1 | 2017 | 574 | 0.120 |
Why?
|
Administration, Inhalation | 1 | 2018 | 1169 | 0.120 |
Why?
|
Anemia, Sickle Cell | 1 | 2023 | 1065 | 0.120 |
Why?
|
Vitamin D Deficiency | 2 | 2021 | 1388 | 0.120 |
Why?
|
Contrast Media | 3 | 2018 | 5334 | 0.120 |
Why?
|
Societies, Medical | 3 | 2024 | 3967 | 0.120 |
Why?
|
Treatment Outcome | 7 | 2020 | 65485 | 0.120 |
Why?
|
Algorithms | 3 | 2024 | 14199 | 0.120 |
Why?
|
Acromegaly | 1 | 2017 | 316 | 0.110 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2020 | 10778 | 0.110 |
Why?
|
Cross-Sectional Studies | 6 | 2020 | 26384 | 0.110 |
Why?
|
Rare Diseases | 1 | 2019 | 630 | 0.110 |
Why?
|
Porosity | 1 | 2014 | 352 | 0.110 |
Why?
|
Menopause | 1 | 2022 | 1656 | 0.110 |
Why?
|
Glycosylation | 1 | 2017 | 1101 | 0.110 |
Why?
|
Tibial Fractures | 1 | 2017 | 276 | 0.110 |
Why?
|
Postprandial Period | 1 | 2015 | 320 | 0.110 |
Why?
|
Estrogen Replacement Therapy | 1 | 2020 | 1209 | 0.110 |
Why?
|
Home Care Services | 1 | 2020 | 660 | 0.110 |
Why?
|
Abdominal Fat | 1 | 2015 | 221 | 0.110 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 1076 | 0.100 |
Why?
|
Case-Control Studies | 3 | 2015 | 22294 | 0.100 |
Why?
|
Hormones | 1 | 2016 | 871 | 0.100 |
Why?
|
Health Resources | 1 | 2019 | 951 | 0.100 |
Why?
|
Patient Admission | 2 | 2019 | 1369 | 0.100 |
Why?
|
Bed Rest | 1 | 2012 | 83 | 0.100 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4862 | 0.100 |
Why?
|
Vitamin D | 3 | 2021 | 3311 | 0.100 |
Why?
|
Radius Fractures | 1 | 2017 | 515 | 0.100 |
Why?
|
Adrenal Cortex Hormones | 1 | 2020 | 1893 | 0.090 |
Why?
|
Mice, Inbred C57BL | 2 | 2022 | 22381 | 0.090 |
Why?
|
Procollagen | 1 | 2011 | 189 | 0.090 |
Why?
|
Animals | 10 | 2024 | 169408 | 0.090 |
Why?
|
Phantoms, Imaging | 3 | 2019 | 2533 | 0.090 |
Why?
|
Osteocalcin | 1 | 2011 | 277 | 0.090 |
Why?
|
Longitudinal Studies | 4 | 2023 | 14795 | 0.090 |
Why?
|
Incidence | 3 | 2019 | 21545 | 0.090 |
Why?
|
Time Factors | 5 | 2024 | 40266 | 0.090 |
Why?
|
Anti-Ulcer Agents | 1 | 2011 | 112 | 0.090 |
Why?
|
Mesenchymal Stem Cell Transplantation | 1 | 2016 | 507 | 0.090 |
Why?
|
Molecular Imaging | 1 | 2017 | 826 | 0.090 |
Why?
|
Young Adult | 10 | 2023 | 60110 | 0.090 |
Why?
|
Drug Therapy, Combination | 1 | 2020 | 6320 | 0.090 |
Why?
|
Polysaccharides | 1 | 2017 | 1024 | 0.090 |
Why?
|
Cell Count | 1 | 2014 | 1833 | 0.090 |
Why?
|
Recurrence | 2 | 2020 | 8512 | 0.090 |
Why?
|
Estrogens | 1 | 2017 | 1537 | 0.090 |
Why?
|
Advisory Committees | 2 | 2024 | 797 | 0.090 |
Why?
|
Pharmaceutical Preparations | 1 | 2018 | 1088 | 0.080 |
Why?
|
Pilot Projects | 2 | 2020 | 8742 | 0.080 |
Why?
|
Prospective Studies | 5 | 2022 | 54950 | 0.080 |
Why?
|
Acute Kidney Injury | 1 | 2022 | 1936 | 0.080 |
Why?
|
Follow-Up Studies | 5 | 2019 | 39394 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2537 | 0.080 |
Why?
|
Vision, Low | 1 | 2011 | 162 | 0.080 |
Why?
|
Kaplan-Meier Estimate | 2 | 2017 | 6546 | 0.080 |
Why?
|
Nephritis | 1 | 2009 | 147 | 0.080 |
Why?
|
Calcium | 3 | 2012 | 5792 | 0.080 |
Why?
|
Dietary Supplements | 1 | 2021 | 3442 | 0.080 |
Why?
|
Genetic Markers | 2 | 2012 | 2604 | 0.080 |
Why?
|
Fasting | 1 | 2014 | 1610 | 0.080 |
Why?
|
Cholesterol, HDL | 1 | 2015 | 1820 | 0.080 |
Why?
|
Neutrophils | 1 | 2021 | 3785 | 0.070 |
Why?
|
Neoplasms | 3 | 2023 | 22390 | 0.070 |
Why?
|
Collagen Type I | 1 | 2011 | 620 | 0.070 |
Why?
|
Hip Joint | 1 | 2014 | 1018 | 0.070 |
Why?
|
Calcinosis | 1 | 2016 | 1481 | 0.070 |
Why?
|
Choroidal Neovascularization | 1 | 2011 | 364 | 0.070 |
Why?
|
Body Weight | 2 | 2016 | 4628 | 0.070 |
Why?
|
Blindness | 1 | 2011 | 587 | 0.070 |
Why?
|
Boston | 1 | 2020 | 9375 | 0.070 |
Why?
|
Aged, 80 and over | 6 | 2020 | 59738 | 0.070 |
Why?
|
Cyclic AMP | 1 | 2010 | 1470 | 0.070 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2016 | 3782 | 0.070 |
Why?
|
Gastrointestinal Agents | 1 | 2011 | 510 | 0.070 |
Why?
|
Double-Blind Method | 1 | 2020 | 12469 | 0.060 |
Why?
|
Cholesterol | 1 | 2015 | 2913 | 0.060 |
Why?
|
Canada | 1 | 2011 | 2129 | 0.060 |
Why?
|
Premenopause | 2 | 2022 | 1039 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2017 | 12563 | 0.060 |
Why?
|
Cell Lineage | 1 | 2014 | 2576 | 0.060 |
Why?
|
Radiographic Image Interpretation, Computer-Assisted | 1 | 2012 | 1232 | 0.060 |
Why?
|
Immunoglobulin G | 1 | 2017 | 4568 | 0.060 |
Why?
|
Angiogenesis Inhibitors | 1 | 2015 | 2059 | 0.060 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2022 | 4642 | 0.060 |
Why?
|
Cohort Studies | 5 | 2021 | 41800 | 0.060 |
Why?
|
Bone Matrix | 1 | 2024 | 127 | 0.060 |
Why?
|
Spinal Fractures | 1 | 2011 | 712 | 0.060 |
Why?
|
Adaptor Proteins, Signal Transducing | 2 | 2012 | 2911 | 0.060 |
Why?
|
Europe | 1 | 2011 | 3441 | 0.060 |
Why?
|
Medication Adherence | 1 | 2016 | 2192 | 0.060 |
Why?
|
Macular Degeneration | 1 | 2011 | 1016 | 0.050 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 3814 | 0.050 |
Why?
|
Mice | 5 | 2022 | 82074 | 0.050 |
Why?
|
Cardiovascular Diseases | 2 | 2019 | 15662 | 0.050 |
Why?
|
C-Reactive Protein | 1 | 2015 | 3858 | 0.050 |
Why?
|
Immunosuppressive Agents | 1 | 2016 | 4207 | 0.050 |
Why?
|
Spectrum Analysis, Raman | 1 | 2024 | 253 | 0.050 |
Why?
|
Telemedicine | 1 | 2020 | 3109 | 0.050 |
Why?
|
Mexican Americans | 1 | 2003 | 165 | 0.050 |
Why?
|
Guideline Adherence | 1 | 2012 | 2240 | 0.050 |
Why?
|
Sickness Impact Profile | 1 | 2003 | 299 | 0.050 |
Why?
|
Atrial Fibrillation | 1 | 2020 | 5176 | 0.050 |
Why?
|
Aromatase Inhibitors | 2 | 2017 | 519 | 0.050 |
Why?
|
Tooth Extraction | 1 | 2022 | 229 | 0.050 |
Why?
|
Tissue Distribution | 2 | 2016 | 2299 | 0.050 |
Why?
|
Arginine | 1 | 2024 | 932 | 0.050 |
Why?
|
Bicarbonates | 1 | 2022 | 292 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 81892 | 0.050 |
Why?
|
B-Lymphocytes | 1 | 2014 | 4794 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2016 | 3250 | 0.040 |
Why?
|
Patient Compliance | 1 | 2010 | 2701 | 0.040 |
Why?
|
Lysine | 1 | 2024 | 1000 | 0.040 |
Why?
|
Blood Glucose | 1 | 2014 | 6434 | 0.040 |
Why?
|
Alendronate | 1 | 2021 | 174 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2019 | 7956 | 0.040 |
Why?
|
Sex Factors | 2 | 2017 | 10641 | 0.040 |
Why?
|
Glioblastoma | 1 | 2015 | 3525 | 0.040 |
Why?
|
Vision, Ocular | 1 | 2003 | 458 | 0.040 |
Why?
|
Peptides | 1 | 2011 | 4353 | 0.040 |
Why?
|
Odds Ratio | 1 | 2011 | 9682 | 0.040 |
Why?
|
Peptide Fragments | 1 | 2011 | 5150 | 0.040 |
Why?
|
Insurance Claim Review | 2 | 2016 | 746 | 0.040 |
Why?
|
Diabetes Mellitus | 1 | 2016 | 5892 | 0.040 |
Why?
|
Coated Materials, Biocompatible | 1 | 2020 | 311 | 0.040 |
Why?
|
Durapatite | 1 | 2019 | 167 | 0.040 |
Why?
|
Brain Neoplasms | 2 | 2020 | 9213 | 0.040 |
Why?
|
Age of Onset | 1 | 2024 | 3346 | 0.040 |
Why?
|
Cardiology Service, Hospital | 1 | 2019 | 242 | 0.030 |
Why?
|
Four-Dimensional Computed Tomography | 1 | 2018 | 141 | 0.030 |
Why?
|
Lupus Erythematosus, Systemic | 1 | 2009 | 2171 | 0.030 |
Why?
|
Perfusion Imaging | 1 | 2018 | 196 | 0.030 |
Why?
|
Spin Labels | 1 | 2018 | 339 | 0.030 |
Why?
|
Fertility Agents, Female | 1 | 2017 | 101 | 0.030 |
Why?
|
T-Lymphocytes | 1 | 2014 | 10276 | 0.030 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2017 | 131 | 0.030 |
Why?
|
Calcium, Dietary | 1 | 2019 | 533 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2018 | 210 | 0.030 |
Why?
|
Amino Acids | 1 | 2022 | 1716 | 0.030 |
Why?
|
Laminectomy | 1 | 2016 | 226 | 0.030 |
Why?
|
Estrogens, Conjugated (USP) | 1 | 2017 | 277 | 0.030 |
Why?
|
Research Design | 1 | 2011 | 6213 | 0.030 |
Why?
|
Leuprolide | 1 | 2017 | 313 | 0.030 |
Why?
|
Rats, Inbred F344 | 1 | 2016 | 825 | 0.030 |
Why?
|
Carbocyanines | 1 | 2015 | 177 | 0.030 |
Why?
|
Adolescent | 5 | 2023 | 89247 | 0.030 |
Why?
|
Antibodies, Monoclonal | 1 | 2011 | 9264 | 0.030 |
Why?
|
Hydrodynamics | 1 | 2015 | 167 | 0.030 |
Why?
|
Metal Nanoparticles | 1 | 2018 | 406 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2019 | 714 | 0.030 |
Why?
|
Psychometrics | 1 | 2003 | 3066 | 0.030 |
Why?
|
Optics and Photonics | 1 | 2015 | 307 | 0.030 |
Why?
|
Drug Delivery Systems | 1 | 2024 | 2238 | 0.030 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2015 | 690 | 0.030 |
Why?
|
Women's Health | 1 | 2022 | 2081 | 0.030 |
Why?
|
Angiography | 1 | 2018 | 1598 | 0.030 |
Why?
|
Head-Down Tilt | 1 | 2012 | 67 | 0.030 |
Why?
|
Microscopy, Phase-Contrast | 1 | 2012 | 110 | 0.030 |
Why?
|
Human Growth Hormone | 1 | 2017 | 648 | 0.030 |
Why?
|
Eating | 1 | 2019 | 1542 | 0.020 |
Why?
|
Postural Balance | 1 | 2016 | 639 | 0.020 |
Why?
|
Equipment Design | 1 | 2020 | 3529 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2016 | 1081 | 0.020 |
Why?
|
Finite Element Analysis | 1 | 2013 | 442 | 0.020 |
Why?
|
Phosphorus | 1 | 2012 | 336 | 0.020 |
Why?
|
Gonadotropin-Releasing Hormone | 1 | 2017 | 1149 | 0.020 |
Why?
|
Weight-Bearing | 1 | 2013 | 534 | 0.020 |
Why?
|
Forecasting | 1 | 2020 | 2946 | 0.020 |
Why?
|
Cervical Vertebrae | 1 | 2016 | 982 | 0.020 |
Why?
|
Community Pharmacy Services | 1 | 2009 | 52 | 0.020 |
Why?
|
Androgens | 1 | 2017 | 1285 | 0.020 |
Why?
|
Databases, Factual | 2 | 2019 | 8095 | 0.020 |
Why?
|
Nanotechnology | 1 | 2015 | 714 | 0.020 |
Why?
|
Body Size | 1 | 2012 | 463 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2015 | 1197 | 0.020 |
Why?
|
Vaccination | 1 | 2021 | 3436 | 0.020 |
Why?
|
Accidental Falls | 1 | 2016 | 1080 | 0.020 |
Why?
|
Temperature | 1 | 2015 | 2235 | 0.020 |
Why?
|
Physical Fitness | 1 | 2012 | 744 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2012 | 2231 | 0.020 |
Why?
|
Medical Records Systems, Computerized | 1 | 2012 | 1196 | 0.020 |
Why?
|
Healthcare Disparities | 1 | 2021 | 3421 | 0.020 |
Why?
|
Residence Characteristics | 1 | 2015 | 2122 | 0.010 |
Why?
|
Administration, Oral | 1 | 2012 | 4042 | 0.010 |
Why?
|
Nanoparticles | 1 | 2016 | 1989 | 0.010 |
Why?
|
Costs and Cost Analysis | 1 | 2009 | 1669 | 0.010 |
Why?
|
Sensitivity and Specificity | 1 | 2018 | 14751 | 0.010 |
Why?
|
Los Angeles | 1 | 2003 | 245 | 0.010 |
Why?
|
Prevalence | 1 | 2019 | 15875 | 0.010 |
Why?
|
Visual Acuity | 1 | 2011 | 2714 | 0.010 |
Why?
|
Diagnosis, Differential | 1 | 2016 | 13020 | 0.010 |
Why?
|
Age Factors | 1 | 2017 | 18454 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2009 | 2783 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2015 | 9081 | 0.010 |
Why?
|
Insurance, Health | 1 | 2009 | 2518 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2020 | 11229 | 0.010 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2015 | 9442 | 0.010 |
Why?
|
Vision Disorders | 1 | 2003 | 1093 | 0.010 |
Why?
|
Kidney Transplantation | 1 | 2009 | 4265 | 0.010 |
Why?
|
Child | 1 | 2022 | 80969 | 0.010 |
Why?
|
Activities of Daily Living | 1 | 2003 | 2433 | 0.010 |
Why?
|
Language | 1 | 2003 | 1559 | 0.010 |
Why?
|
Hospitalization | 1 | 2009 | 10845 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2015 | 36861 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2003 | 20244 | 0.000 |
Why?
|